Skip to main content

Table 4 Specific adverse events with an incidence ≥2% in one or more treatment group by system organ class

From: A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

  Omarigliptin N = 153 Placebo N = 153
General disorders and administration site conditions
 Chest discomfort 3 (3.0) 0 (0.0)
Infections and infestations
 Influenza 3 (2.0) 0 (0.0)
 Nasopharyngitis 4 (2.6) 5 (3.3)
 Rhinitis 3 (2.0) 1 (0.7)
 Upper respiratory tract infection 4 (2.6) 9 (5.9)
 Urinary tract infection 9 (5.9) 3 (2.0)
Investigations
 Blood creatine phosphokinase increased 2 (1.3) 3 (2.0)
 Blood glucose increased 1 (0.7) 3 (2.0)
 Lipase increased 5 (3.3) 1 (0.7)
Metabolism and nutrition disorders
 Hyperglycemia 3 (2.0) 6 (3.9)
 Hypoglycemia 18 (11.8) 13 (8.5)
Musculoskeletal and connective tissue disorders
 Arthralgia 3 (2.0) 3 (2.0)
 Back pain 4 (2.6) 3 (2.0)
Nervous system disorders
 Headache 0 (0.0) 3 (2.0)